Beau Cygne Pty Ltd

Status: External administration (in receivership/liquidation)
Australian Company Number: 168338707
Australian Business Number: 53168338707
Registration date: 3rd March 2014
Type: Australian proprietary company
Class: Limited by Shares
Subclass: Proprietary other
last updated


Beau Cygne Pty Ltd is a limited by shares, Australian proprietary company. This corporation was registered on 2014-03-03 and was issued with the 168338707 ACN. Its Australian Business Number is 53168338707. Since 2014-09-24, the company is headquartered in VIC, post code 3202. The previous headquarters were located in VIC 3202 (from 2014-03-03 to 2014-09-24). Beau Cygne Pty Ltd was registered for the GST on 2014-03-03, up until 2017-06-29. The company has also used 1 business name, namely Quest Moorabbin from 2014-06-16 to 2017-02-11. The above data comes from the ABN database which was updated on 2017-07-25.


Details for ABN 53168338707

Type: Australian Private Company

ABN Status

Status From To
Active 3rd March 2014 current

Main Name

Name From To
Beau Cygne Pty Ltd 3rd March 2014 current

Business Names

Name From To
Quest Moorabbin 16th June 2014 11th February 2017

Main Location

Location From To
VIC 3202 24th September 2014 current
VIC 3202 3rd March 2014 24th September 2014

Goods & Services Tax (GST)

Status From To
Registered 3rd March 2014 29th June 2017


Find company

VIC 3202 Location

2018 © - ABN Lookup, ACN, ABR, ABN Search. All rights reserved.
Contact us:
Terms of Use and Privacy Policy

Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2018 (, and, ©Intellectual Property Government Open Data 2018, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.